

# Uncovering the hidden costs of Take-Home Cancer Drugs

Lamb-Palmer D,<sup>1</sup> Loschmann C,<sup>1</sup> Henricks P,<sup>2,3</sup> Shen J,<sup>1</sup> Dowson JP,<sup>2</sup> Mohideen S<sup>2</sup>

<sup>1</sup> PDCI Market Access Inc., a division of McKesson Canada Corporation, Ottawa, Ontario, Canada

<sup>2</sup> PDCI Market Access Inc., a division of McKesson Canada Corporation, Toronto Ontario, Canada

<sup>3</sup> CAPT Board of Directors, Member at Large



## BACKGROUND

The Canadian Cancer Society has partnered with PDCI to identify the gaps in access to Take Home Cancer Drugs (THCDs) in select provinces. Coverage eligibility for THCD varies significantly across Canadian provinces creating interprovincial differences.

## OBJECTIVE

The objective of this analysis was to identify the gaps in access to oral THCD in Canada by modelling the financial burden to patients in Ontario (ON), Nova Scotia (NS), and New Brunswick (NB) and reporting on barriers to access.

## RESULTS


The analysis identified gross costs associated with funding THCD treatment ranging between \$19.4 and \$51.9 million. Provincially, the incremental cost to implement a THCD plan would be between \$12.3 and \$30.9 million in Ontario, \$0.9 and \$2.9 million in New Brunswick and \$0.7 and \$2.8 million in Nova Scotia. Today, these gaps are borne by third parties, including manufacturer sponsored patient support programs and the patients themselves, or result in reduced utilization and associated life benefits.

### Components of Current Drug Plan Design for THCDs

Primary plan reimbursement for patients who are prescribed THCDs can be paid by several different drug plans, both private and public.

Patients with high out-of-pocket costs will seek Secondary coverage to fill gaps in Primary Coverage.

#### Secondary coverage options for patients on THCDs




Publicly funded Catastrophic drug plans often have household-income based deductibles. Out-of-pocket costs exceeding the deductible limits are then reimbursed by the Catastrophic plans.

PROVINCE	CATASTROPHIC DRUG PROGRAM	DRUG PLAN: COST TO THE PATIENT
British Columbia	BC Cancer	Free of charge for THCD on formulary
Manitoba	Cancer Care Manitoba	Free of charge for THCD on formulary
Saskatchewan	Saskatchewan Cancer Agency	Free of charge for THCD on formulary
Alberta	Outpatient Cancer Drug Benefit Program	Free of charge for THCD on formulary
Ontario	Trillium Drug Program	Deductible: 4% of household income
Quebec	RAMQ Under 65	Annual OOP maximum: \$1,144
Nova Scotia	Take Home Cancer Drug Fund	Deductible: 4% of net family income
New Brunswick	New Brunswick Drug Plan	Annual premiums based on income
Newfoundland & Labrador	Assurance Plan	Deductible: 5-10% of net annual income
Prince Edward Island	Catastrophic Drug Program	Deductible: 3-12% of annual income

### Current Costs

In this analysis, PDCI estimates a gap in current spending on THCDs of \$0.6 million in New Brunswick, \$0.3 million in Nova Scotia, and \$5.9 million in Ontario.



### THCD Plan Parameters

<b>Beneficiary Eligibility</b>	Patients without or with insufficient drug insurance benefits
<b>Replaces</b>	'Trillium-like' drug programs
<b>Drug Coverage</b>	Secondary payer, i.e., supplemental to existing benefits
<b>Model Basis</b>	Coverage based on OHIP+ system in Ontario
<b>Limitation</b>	Plan coverage limited to existing provincial formulary coverage

## METHODS

A five-step approach was used to build the model: 1.) Identification of cancer types and incidence, 2.) Search for oral THCDs covered in each jurisdiction, 3.) Identification of drug plan design by age and province, 4.) Defining the Canadian patient population by age, income, province, and cancer type, and 5.) Calculation of costs and utilization based on an assessment of private and public claims data.

Subsequent interviews with Patient Support Program (PSP) managers was conducted to understand the patient experience and to highlight potential barriers to access.

## DISCUSSION

• THCDs are an essential part of the Canadian health system; especially in a time of crisis. In Canada, inequities in coverage create a significant gap paid as patient out-of-pocket expenses.

• While the range of costs needed to implement greater universality of THCD coverage may seem large (relative to each province's population), other provinces' experiences demonstrate the coverage gaps can be filled, removing the financial stress and burden from patients.

• In a small survey of oral oncology PSPs, it is reported that significant financial and drug access support is currently being provided to patients aged 40-65 years and older.

• Without patient assistance programs, patients would be stranded with current government programs as THCDs are not consistently covered by public drug programs and the specialized care and management of oral oncology patients may not be fully supported.

• This research highlights the financial gaps, and variability of coverage for patients based on where they live or their type of cancer. If coverage gaps do not appear evident to policymakers and patients, it may be attributed to financial and other support being offered by PSPs and their pharmaceutical company sponsors.

• As the concern of access to THCD continue to evolve, cancer agencies like the Canadian Cancer Society will help to shape health policies to support those living with the disease. This research identifies important cancer information for all Canadians and a call to action for policymakers to increase support services to help people better manage life with cancer.

### Future Cost for a THCD Plan

PDCI's analysis of current THCD spending shows an underutilization of THCDs in provinces without comprehensive and accessible drug programs. The introduction of a THCD program would potentially increase the number of patients treated. The PDCI model predicted an increased utilization gap ranging between \$12.1M and \$44.6M.

#### Summary of Incremental government costs to implement a THCD plan

Province	Current Government Costs	Current Spending Gap	Increased Coverage Effect	Increased Utilization Effect	THCD Plan Cost (Gross)	Incremental Cost (Gross)	Incremental Cost (Net of PLA)
New Brunswick	\$2.4M	+\$0.6M	+\$0.05M	+\$0.6M - +\$3.5M	\$1.3M - \$4.1M	\$3.6M - \$6.5M	\$0.9M - \$2.9M
Nova Scotia	\$3.3M	+\$0.3M	+\$0.05M	+\$0.7M - +\$3.7M	\$1.1M - \$4.0M	\$4.3M - \$7.3M	\$0.7M - \$2.8M
Ontario	\$59.9M	+\$5.9M	+\$0.9M	+\$10.8M - +\$37.4M	\$17.5M - \$44.2M	\$77.5M - \$104.1M	\$12.3M - \$30.9M
<b>TOTAL</b>	<b>\$66.0M</b>	<b>+\$6.4M</b>	<b>+\$1.0M</b>	<b>+\$12.1M - +\$44.6M</b>	<b>\$19.4M - \$51.9M</b>	<b>\$85.4M - \$117.9M</b>	<b>\$13.9M - \$36.7M</b>

## REFERENCES

- Canadian Cancer Society. Cancer Statistics Online 2021. [cited 15 Apr 2021]. Available from: <https://action.cancer.ca/en/research/cancer-statistics>.
- Canadian Cancer Society. Access to cancer drugs and diagnostics Canadian Cancer Society. 2021. [cited 15 Apr 2021]. Available from: <https://action.cancer.ca/en/get-involved/advocacy/what-we-are-doing/drug-access>.
- Sirin M, Franco EL, Quesnel-Vallée A. 2019. Inter- and intraprovincial inequities in public coverage of cancer drug programs across Canada: a plea for the establishment of a pan-Canadian pharmacare program. *Curr. Oncol.* 26(4):266-2 doi: 10.3747/co.26.4867.
- IQVIA. Global Oncology Trends 2019. IQVIA Institute, 30 May 2019.
- Barua B, Jacques D, Esmail N. Provincial Drug Coverage for Vulnerable Canadians. *Fraser Institute*. 2018.
- Government of Ontario. Get help with high prescription drug costs Online: Government of Ontario, 2021. [cited 16 Apr 2021]. Available from: <https://www.ontario.ca/page/get-help-high-prescription-drug-costs#section-5>.
- Government of Quebec. Amount to pay for prescription drugs. 2021. [cited 15 Apr 2021]. Available from: <https://www.ramq.gouv.qc.ca/en/clients/prescription-drug-insurance/amount-pay-prescription-drugs>.
- Nova Scotia Health Authority. Take-Home Cancer Drug Fund Online. [cited 16 Apr 2021]. Available from: <http://www.cdhb.nshealth.ca/node/20239>.
- Government of New Brunswick. Premiums and Copayments Online 2021. [cited 16 Apr 2021]. Available from: <https://www2.gnb.ca/content/gnb/en/departments/health/MedicarePrescriptionDrugPlan/NBDrugPlan/Premiums.html>.

To view a copy of the full White Paper, please visit <https://www.pdci.ca/resources/publications/>

THCD: Take Home Cancer Drugs; OHIP: Ontario Health Insurance Plan